Skip to main content

Table 1 Patients’ Characteristics

From: Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study

 N = 285%
Gender
Male14150.5
Female14449.5
Age at surgery(Median)25(17–37) 
BMI(kg/m2) (Median)22.6(19–27) 
Disease duration (months)48(23.7–120) 
Smoking
Never22277.9
Prior5619.6
Current72.5
Disease extent
E2 Left-side colitis3512.3
E3 Pancolitis25087.7
Disease Severity
S2 Moderate UC19969.8
S3 Severe UC8630.2
Disease activity
Acute1893.7
chronic2676.3
Medication history
Steroid9031.6
6-MP or MTX19668.8
Immunosuppressant
Non-biologics7727
Anti-TNF18364.2
Anti-TNF adding Vedolizumab258.8
Operation type
Laparoscopy20973.3
Open7626.7
Operation performed
Total abdominal colectomy
+end stoma
9232.3
Protectomy + IPAA with ileostomy19367.7
Preoperative labs
Leukocyte(× 103/uL) (Median)9.4(6.6–12.5)
Platelet(×103/uL) (Median)350(274–475)
Albumin(g/dl) (Median)3.7(3.3–4.0)
  1. All values expressed as median (range) or n (%)
  2. BMI body mass index, 6-MP 6-mercaptopurine, MTX methotrexate, IPAA ileal pouch-anal anastomosis, TNF tumor necrosis factor